# A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

> **NCT01333865** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 25 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Memantine

## Key facts

- **NCT ID:** NCT01333865
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333865, "A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01333865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*